Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atea Pharmaceuticals, Inc.AVIR · Entity 5580 | EVP, Chief Accounting Officer | January 31, 2026 | February 03, 2026 |
| Mersana Therapeutics, Inc.MRSN · Entity 69982 | Vice President of Finance | January 23, 2019 | January 25, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atea Pharmaceuticals, Inc.
Report date January 31, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 79,329 |
Ending reported balance
After 2026-01-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-31 · Exercise / conversion · Acquired 41,333 · Balance 91,461 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-01-31 · Tax withholding · Disposed 12,132 · Balance 79,329 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-01-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-31 · Exercise / conversion · Disposed 33,333 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-01-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-31 · Exercise / conversion · Disposed 8,000 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.24 · Expires 2036-01-30 | Direct | 108,000 |
Reported balance
After 2026-01-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-31 · Grant · Acquired 108,000 · Balance 108,000 F4: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.
F3: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.
F4: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.
Mersana Therapeutics, Inc.
Report date January 23, 2019 · Filed January 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2029-01-23 | Direct | 30,750 |
Reported balance
After 2019-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-23 · Grant · Acquired 30,750 · Balance 30,750 F1: The options vest in equal quarterly installments over the first four years after the vesting commencement date, January 23, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in equal quarterly installments over the first four years after the vesting commencement date, January 23, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2026 Filed Feb 3, 2026 19:42 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 108,000 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001193125-26-036261 · ownership.xml · derivative · entry 5 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,000 Underlying: Common Stock · 108,000 shares Expires 2036-01-30 F4 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 19:42 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-036261 · ownership.xml · derivative · entry 4 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. F3 · derivative.expiration_date: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 19:42 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-036261 · ownership.xml · derivative · entry 3 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. F2 · derivative.expiration_date: The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 19:42 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Tax withholdingCommon Stock | 12,132 | $4.24 | $51,439.68 |
DisclosureSEC source: 0001193125-26-036261 · ownership.xml · nonDerivative · entry 2 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,329 Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 19:42 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 41,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-036261 · ownership.xml · nonDerivative · entry 1 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 120,100 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0000950170-25-013844 · ownership.xml · derivative · entry 6 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,100 Underlying: Common Stock · 120,100 shares Expires 2035-01-30 F5 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013844 · ownership.xml · derivative · entry 5 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer. F4 · derivative.expiration_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013844 · ownership.xml · derivative · entry 4 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,333 Underlying: Common Stock · 33,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. F3 · derivative.expiration_date: The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Tax withholdingCommon Stock | 12,062 | $3.06 | $36,909.72 |
DisclosureSEC source: 0000950170-25-013844 · ownership.xml · nonDerivative · entry 3 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,128 Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantCommon Stock | 8,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-013844 · ownership.xml · nonDerivative · entry 2 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,190 F2 · price: Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units ("PSUs"). Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 33,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-013844 · ownership.xml · nonDerivative · entry 1 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:26 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | SaleCommon Stock | 12,477 | $3.84 | $47,904.19 |
DisclosureSEC source: 0000950170-24-010969 · ownership.xml · nonDerivative · entry 2 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,857 F2 · shares: Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 15, 2022. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:26 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 120,100 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000950170-24-010969 · ownership.xml · derivative · entry 4 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,100 Underlying: Common Stock · 120,100 shares Expires 2034-01-30 F4 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:26 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 33,334 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-010969 · ownership.xml · derivative · entry 3 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,666 Underlying: Common Stock · 33,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. F3 · derivative.expiration_date: The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:26 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 33,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-010969 · ownership.xml · nonDerivative · entry 1 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:38 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0000899243-23-003629 · doc4.xml · derivative · entry 2 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2033-01-30 F3 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2023 such that the option is fully vested on January 31, 2027. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:38 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-003629 · doc4.xml · derivative · entry 1 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026. F2 · derivative.expiration_date: The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 17:15 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0000899243-22-004183 · doc4.xml · derivative · entry 1 Foster Wayne · CIK 0001709769 · EVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2032-01-30 F1 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2022. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 16:50 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 71,750 | $0.00 Strike: $73.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003866 · doc4.xml · derivative · entry 1 Foster Wayne · CIK 0001709769 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,750 Underlying: Common Stock · 71,750 shares Expires 2031-01-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 29, 2021. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 17:40 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0000899243-20-029953 · doc4.xml · derivative · entry 1 Foster Wayne · CIK 0001709769 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-10-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 equal monthy installments following October 29, 2020. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 16:05 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (right to buy) · Derivative | 30,750 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0001104659-19-003410 · a4.xml · derivative · entry 1 Foster Wayne · CIK 0001709769 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,750 Underlying: Common Stock · 30,750 shares Expires 2029-01-23 F1 · derivative.exercise_date: The options vest in equal quarterly installments over the first four years after the vesting commencement date, January 23, 2019. Read SEC document |
| February 02, 2018 Filed Feb 6, 2018 16:26 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (right to buy) · Derivative | 20,250 | $0.00 Strike: $14.23 | $0.00 |
DisclosureSEC source: 0001104659-18-006858 · a4.xml · derivative · entry 1 Foster Wayne · CIK 0001709769 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,250 Underlying: Common Stock · 20,250 shares Expires 2028-02-01 F1 · derivative.exercise_date: The options vest in equal quarterly installments over the first four years after the vesting commencement date, February 2, 2018. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:01 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionOption to Purchase Common Stock · Derivative | 2,499 | $0.00 Strike: $6.98 | $0.00 |
DisclosureSEC source: 0001104659-18-005845 · a4.xml · derivative · entry 8 Foster Wayne · CIK 0001709769 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,834 Underlying: Common Stock · 2,499 shares Expires 2027-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The original option grant for 13,333 option shares vests in equal quarterly installments over the first four years after the vesting commencement date, March 14, 2017. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:01 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionOption to Purchase Common Stock · Derivative | 3,262 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001104659-18-005845 · a4.xml · derivative · entry 7 Foster Wayne · CIK 0001709769 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,155 Underlying: Common Stock · 3,262 shares Expires 2026-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The original option grant for 13,047 option shares vests in equal quarterly installments over the first four years after the vesting commencement date, July 1, 2016. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:01 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionOption to Purchase Common Stock · Derivative | 8,055 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001104659-18-005845 · a4.xml · derivative · entry 6 Foster Wayne · CIK 0001709769 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,084 Underlying: Common Stock · 8,055 shares Expires 2025-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The original option grant for 32,222 option shares vests in equal quarterly installments over the first four years after the vesting commencement date, June 12, 2015. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:01 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionOption to Purchase Common Stock · Derivative | 889 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001104659-18-005845 · a4.xml · derivative · entry 5 Foster Wayne · CIK 0001709769 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 889 Underlying: Common Stock · 889 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The original option grant for 3,555 option shares vests in equal quarterly installments over the first four years after the vesting commencement date, January 2, 2015. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:01 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 2,499 | $6.98 | $17,443.02 |
DisclosureSEC source: 0001104659-18-005845 · a4.xml · nonDerivative · entry 4 Foster Wayne · CIK 0001709769 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:01 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 3,262 | $4.10 | $13,374.20 |
DisclosureSEC source: 0001104659-18-005845 · a4.xml · nonDerivative · entry 3 Foster Wayne · CIK 0001709769 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:01 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 8,055 | $1.53 | $12,324.15 |
DisclosureSEC source: 0001104659-18-005845 · a4.xml · nonDerivative · entry 2 Foster Wayne · CIK 0001709769 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:01 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | Exercise / conversionCommon Stock | 889 | $1.62 | $1,440.18 |
DisclosureSEC source: 0001104659-18-005845 · a4.xml · nonDerivative · entry 1 Foster Wayne · CIK 0001709769 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.